Christian Meyer
Director de Operaciones en VectivBio AG .
Cargos activos de Christian Meyer
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director de Operaciones | - | - |
Historial de carrera de Christian Meyer
Antiguos cargos conocidos de Christian Meyer.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Director Técnico/Científico/I+D | 01/11/2017 | 01/06/2019 |
UNIQURE N.V. | Director Técnico/Científico/I+D | 01/09/2013 | 01/11/2017 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Director Técnico/Científico/I+D | 01/01/2006 | 01/01/2010 |
Consejero General | 01/01/2006 | 01/01/2010 | |
Therachon AG | Corporate Officer/Principal | - | - |
VECTIVBIO HOLDING AG | Director de Operaciones | 25/05/2021 | - |
Corporate Officer/Principal | 01/06/2019 | 25/05/2021 | |
RSPR Pharma AB
RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Director Técnico/Científico/I+D | 01/01/2006 | 01/01/2010 |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
Formación de Christian Meyer.
University of Copenhagen | Doctorate Degree |
Estadísticas
Internacional
Suiza | 5 |
Dinamarca | 4 |
Países Bajos | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
UNIQURE N.V. | Health Technology |
Empresas privadas | 6 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
RSPR Pharma AB
RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon AG | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Christian Meyer
- Experiencia